Khiron Life Sciences Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
For the six months, revenue was CAD 9.12 million compared to CAD 5.64 million a year ago. Net loss was CAD 7.58 million compared to CAD 10.29 million a year ago. Basic loss per share from continuing operations was CAD 0.04 compared to CAD 0.07 a year ago. Diluted loss per share from continuing operations was CAD 0.04 compared to CAD 0.07 a year ago.